Medtronic Completed the MiniMed Separation as China Proposed Export Bans on Biotech Platforms and City Therapeutics Debuted Up 24.4%, October 19, 2026
Last updated: October 19, 2026
Medtronic exchanged its entire remaining MiniMed stake and exited completely on October 15, China proposed export rules that would bar foreign buyouts of cell and gene therapy and siRNA platforms, and City Therapeutics closed its first session at $22.40, 24.4% above its $18.00 offer.
This briefing covers Friday, October 16 through Sunday, October 18, 2026: the completed MiniMed separation, China’s draft export control catalogue, the IPO cohort’s Friday session, the CHMP’s October opinions, Labcorp’s BioReference deal, Zentalis’ first DENALI survival data, Lonza’s new midterm targets, AbbVie’s UEG Week data, and Monday morning’s scheduled readouts.
How did Medtronic complete the MiniMed separation?
Medtronic exchanged all 252,813,348 of its remaining MiniMed shares for 55,032,401 tendered Medtronic shares and now holds no stake in the diabetes company. The exchange offer was 5.4 times oversubscribed. October 15 was MiniMed’s first day as a fully independent company.
Both companies confirmed completion in October 15 releases, MiniMed’s filed as an 8-K exhibit. The final figures match the results Medtronic published a day earlier: the offer that investors oversubscribed more than five to one closed with the designed discount intact and Medtronic’s exit total. MiniMed chief executive Que Dallara called it “a significant milestone” and said the company’s focus now is “to put that independence to work.” Medtronic chairman and chief executive Geoff Martha said the separation gives each company “a clear strategic focus.” Fractional shares will be paid in cash after the exchange agent sells the aggregated fractions in the open market. Goldman Sachs and BofA Securities were dealer managers.
| Final exchange offer item | Figure | Source |
|---|---|---|
| Medtronic shares accepted | 55,032,401 | MiniMed release (8-K exhibit), Oct 15 |
| MiniMed shares issued | 252,813,348 | Company releases, Oct 15 |
| Oversubscription | 5.4x | Company releases, Oct 15 |
| Final proration factor | 18.289133% | Medtronic final results, Oct 14 |
| Medtronic stake remaining | None | Company releases, Oct 15 |
| Implied shares per MDT share | ~4.59 (our arithmetic) | Computed from release figures |
The first post completion session gave back part of Thursday’s bounce. MiniMed closed Friday at $17.49, down 2.8%, while Medtronic closed at $94.75, down 0.7%. The exchange package of 4.5939 MiniMed shares per Medtronic share was worth $80.35 at Friday’s close against Medtronic’s $94.75, a gap of roughly 15.2% versus the 7% discount the offer was designed around. Both the package value and the gap are our arithmetic from settled closes. MedTech Dive reported that MiniMed starts independent life with about 160 technology service agreements with Medtronic and expects to exit most of them in 2027. Neither completion release mentions index inclusion, which remains the open mechanical question for the float.
What would China’s draft export rules ban?
China’s Ministry of Commerce published a draft update to its export control catalogue on Friday that would ban foreign acquisitions of proprietary Chinese platforms in cell and gene therapy, siRNA, and pathogen gain of function research, while leaving out licensing deals and outsourced research and manufacturing services untouched. Comments are open until November 15.
The draft, reported by Fierce Biotech, also restricts, without banning, full transfers of proprietary drug target identification and verification technologies in cell and gene therapy and siRNA, which would require approval. Out licensing of those same technologies would generally be approved. The scope matters because of the size of the pipe it leaves open: foreign transactions of Chinese biotech assets reached $120 billion as of August 2026, up 36% year over year, per figures Fierce attributed to China’s drug regulators, and PharmCube counts only 5 of 121 cross border out licensing deals in 2026 through July 1 that involved ownership transfer. In other words, the rule targets the rare structure, not the common one. AstraZeneca’s roughly $1 billion acquisition of Gracell Biotechnologies, announced in late 2023 for its FasTCAR platform, would likely not be permitted under the draft, per the same report. A Han Kun partner, Aaron Gu, summarized the draft as “regulating transfers while leaving licensing unconstrained” and called it “significantly better than market expectations.” A rumored May list had included multispecific antibodies, antibody drug conjugates, and protein degraders; the published draft is narrower.
How did the biotech IPO cohort trade on Friday, October 16?
The newest names rallied hard into a broad selloff. City Therapeutics closed its first session at $22.40, 24.4% above the $18.00 offer, while the XBI fell 3.6% and the S&P 500 fell 1.1%. Iambic added 25.9% in its second session. All percentages are our arithmetic from settled closes.
| Company | Offer | Friday close | Vs offer | Session |
|---|---|---|---|---|
| City Therapeutics (CTY) | $18.00 | $22.40 | +24.4% | First session (+24.4%) |
| Iambic (IAM) | $16.00 | $23.81 | +48.8% | Second session (+25.9%) |
| Retension (RTSN) | $12.00 | $14.07 | +17.3% | +15.2%, no disclosure found |
| TRexBio (TRXB) | $14.00 | $14.01 | +0.1% | −1.1% |
The pattern extends the two ended market read this publication put on record Friday: the premium sits with stories that have not yet met a dataset. City priced an upsized $200.0 million offering Thursday night with no clinical data in the pricing release and closed its debut at a 24.4% premium on a day the sector index lost 3.6%. Iambic, the window’s first debut premium, has now run 48.8% above its offer in two sessions. Retension, which debuted broken at a 12.2% discount nine days ago, jumped 15.2% Friday with no company disclosure we could find, and now sits 17.3% above its offer. Neither Iambic nor Retension has published an offering closing release, a check we have run since each priced; City’s closing is expected Monday. The capital is paying for narrative optionality at one end and certainty at the other, and Q3 earnings season, which begins for medtech with Abbott on Wednesday morning, is the first test of whether anything in the middle can earn a premium.
Which drugs did the CHMP endorse at its October meeting?
Europe’s drug committee recommended six new medicines on Friday, led by Eli Lilly’s Foundayo (orforglipron), the first oral small molecule GLP-1 recommended for approval in the EU, for obesity and for type 2 diabetes. RevMed’s Rasonque was endorsed for second line metastatic pancreatic adenocarcinoma.
| Drug | Company | CHMP opinion |
|---|---|---|
| Foundayo (orforglipron) | Eli Lilly | Positive: obesity or overweight with at least one weight related condition; type 2 diabetes |
| Rasonque | Revolution Medicines | Positive: second line metastatic pancreatic adenocarcinoma |
| Yuviwel | Ascendis Pharma | Positive: pediatric achondroplasia |
| Kizfizo | Orphelia Pharma | Positive: glioblastoma multiforme and malignant glioma |
| Ranibizumab and filgrastim biosimilars | Not named in coverage | Positive |
| Label extensions | AstraZeneca (avian flu vaccine), Novo Nordisk (Kyinsu), J&J (Talvey), Ionis (Tryngolza), Pfizer (Tukysa) | Positive |
Per Fierce Pharma’s account of the EMA highlights, Foundayo’s obesity package showed roughly 5% to 11% body weight loss at 72 weeks across doses versus 2% to 2.5% on placebo, and in type 2 diabetes an A1C reduction of about 1.2 to 1.9 percentage points versus 0.4 to 0.8 on placebo, with head to head wins over Farxiga and both doses of oral semaglutide. Those figures are attributed; the EMA’s own highlights page is the primary document. European Commission decisions typically follow within weeks. For Lilly, the opinion opens a second front for the oral obesity franchise it launched in the US as Foundayo; for RevMed, the EU endorsement lands while US investors are still arguing over the FDA review documents’ response rate detail in KRAS G12D patients, a reaction analysts called overdone, per the same report.
What did Labcorp agree to buy from OPKO Health?
Labcorp agreed Thursday to acquire select BioReference Health assets from OPKO for $722 million in cash at closing, adjusted for closing revenues, plus up to $150 million in an earnout tied to 4Kscore test revenue, a total of up to $872 million. Labcorp expects about $250 million of revenue in the first year after close.
The assets cover clinical and women’s health testing, urology, and corrections testing, more than 80 patient service centers, and the 4Kscore blood test, which is FDA approved to help predict the likelihood of aggressive prostate cancer before a biopsy decision. The deal, announced Thursday morning in a joint release, follows Labcorp’s March 2025 purchase of BioReference’s oncology testing businesses for up to $225 million; OPKO chairman and chief executive Phillip Frost said the sale lets OPKO focus its resources on its biopharmaceutical business. Close is subject to regulatory approvals, with no date given. For the diagnostics vertical the transaction continues the consolidation of regional reference labs into the two national networks, with the proprietary test carrying the earnout.
What survival data did Zentalis report from DENALI Part 1b?
Zentalis reported Sunday evening that azenosertib produced median overall survival of 15.8 months in Cyclin E1 positive platinum resistant ovarian cancer, versus 7.5 months in Cyclin E1 negative patients, in an interim analysis of the Part 1b cohort of the DENALI study, published in an ESMO Congress 2026 abstract.
The figures, from a September 2, 2025 data cutoff, cover 102 enrolled patients, 94 of them evaluable for Cyclin E1 status: median overall survival 15.8 months (95% CI, 8.7 to 17.8) in the Cyclin E1 positive group (n=48) and 7.5 months (95% CI, 5.8 to 12.3) in the negative group (n=46), at 400 mg once daily on a five days on, two days off schedule, in patients with one to five prior lines and prior bevacizumab required. The caveats are real: overall survival was a secondary endpoint, the analysis is interim, the biomarker split is retrospective, and the confidence intervals overlap. The company reads the data as supporting Cyclin E1 as a selection biomarker for its WEE1 inhibitor ahead of the Phase 3 ASPENOVA trial; the full presentation is a rapid oral at ESMO in Madrid on Friday, October 23. The readacross to watch is whether a biomarker defined platinum resistant ovarian population can support accelerated development where all comers strategies have repeatedly failed.
What are Lonza’s new midterm targets?
Lonza set new midterm targets at its October 14 capital markets day: low teens average organic sales growth at constant exchange rates over time and a CORE EBITDA margin expanding into the high 30s, alongside a reaffirmed 2026 outlook of 11% to 12% sales growth at a 33% to 34% margin.
Reuters reported the growth ambition as 10% to 13% at constant currency and noted third quarter performance in line with expectations across all businesses. The company said its Vacaville biologics site could reach peak sales of up to 2 billion Swiss francs in the early 2030s, and that it is ready to “double down on bolt on acquisitions.” The Capsules and Health Ingredients divestment to Lone Star Funds for $3 billion, agreed in March, is expected to close by year end, completing the move to a pure play CDMO. The targets land as CDMO capacity decisions become the industry’s quiet constraint: the question for customers is whether high 30s margins and low teens growth can coexist with the capacity pricing that biotech clients absorb.
What long term IBD data did AbbVie present at UEG Week 2026?
AbbVie presented 20 abstracts at UEG Week in Barcelona, headlined by three year Skyrizi maintenance data in ulcerative colitis and roughly four year Rinvoq data in Crohn’s disease. At week 144 of U-ENDURE, clinical remission was 78.9% on 15 mg and 86.6% on 30 mg in as observed analyses.
In the COMMAND maintenance study of risankizumab in ulcerative colitis, week 96 as observed clinical remission ranged from 54.0% to 73.1% and endoscopic remission from 38.8% to 53.5% across advanced therapy naive and experienced patients. Endoscopic remission at week 144 of U-ENDURE was 47.1% and 64.2% by dose. A real world upadacitinib analysis reported clinical response in 70.2% of 497 evaluable Crohn’s patients within 12 weeks, with a median 13 days to first response, and a 514 patient claims analysis found lower IBD related hospitalization (9.5% versus 16.3%) and surgery (6.9% versus 10.6%) rates in patients switched from a TNF inhibitor to upadacitinib rather than cycled to another TNF inhibitor. As observed long term data flatters by design, since discontinuers leave the denominator, but the franchise message is the durability claim both assets now carry into payer conversations. UEG Week runs through October 20.
What else happened over the weekend?
Four smaller items earn a place in the record. The FDA approved Opus Genetics’ RYZUMVI (phentolamine ophthalmic solution) 0.75% for presbyopia on Friday, a supplemental approval making it the second eye drop for age related near vision loss; Viatris holds exclusive US commercialization rights and owes Opus an undisclosed milestone. Novartis discontinued its midstage Fabhalta study in lupus nephritis after the first part, citing “strategic considerations” in a registry update reported by Reuters, with no safety or efficacy explanation given. Estuary Therapeutics launched with $103 million for kidney disease gene therapies, per Fierce Biotech and Endpoints. And Edwards Lifesciences recalled four lots, fewer than 200 units, of Commander M delivery systems for its Sapien M3 mitral valve after three reports of balloons bursting during inflation, with one death and one serious injury recorded as of October 5, per an FDA early alert issued Thursday and reported by MedTech Dive.
What is scheduled for Monday morning, October 19?
Two Phase 3 toplines will be discussed on 8:00 am ET calls announced Sunday evening, with neither outcome yet disclosed: Disc Medicine’s APOLLO trial of bitopertin in erythropoietic protoporphyria, and Veradermics’ study 304 of VDPHL01, its extended release oral minoxidil, in 536 males with mild to moderate pattern hair loss.
Both companies announced the webcasts without releasing results, so Monday’s open is a scheduled disclosure event in both names. For Disc Medicine, APOLLO is the trial the FDA agreed could support its response to the bitopertin complete response letter, making the readout the gating item for the EPP program’s second approval attempt. For Veradermics, study 304 is a new Phase 3, distinct from the positive Phase 2/3 302 study reported in April 2026. City Therapeutics’ IPO closing is also expected Monday. We will cover the outcomes in Tuesday’s edition.
Which stocks moved on Friday, October 16?
Friday was a broad risk off session, with the XBI down 3.6% against a 1.1% decline in the S&P 500, and the day’s distinguishing feature was the IPO cohort rallying against it. All percentages are our arithmetic from settled exchange closes.
| Ticker | Friday close | Move | Context |
|---|---|---|---|
| CTY | $22.40 | +24.4% vs $18.00 offer | First session; upsized $200.0M IPO priced Thursday night |
| IAM | $23.81 | +25.9% | Second session; now +48.8% over the $16.00 offer |
| RTSN | $14.07 | +15.2% | No disclosure found; +17.3% over the $12.00 offer; closing release still absent |
| MMED | $17.49 | −2.8% | First post completion session; package gap to MDT ≈15.2% (ours) |
| IBRX | $9.18 | −8.2% | No company disclosure; now below its pre approval level four sessions after the papillary approval |
| XBI / SPY | $144.32 / $763.25 | −3.6% / −1.1% | Session context |
Frequently asked questions
Does Medtronic still own any of MiniMed?
No. Medtronic exchanged its entire remaining stake of 252,813,348 MiniMed shares for 55,032,401 tendered Medtronic shares and confirmed on October 15, 2026 that it no longer holds an equity stake.
How oversubscribed was the Medtronic MiniMed exchange offer?
5.4 times, per both companies’ October 15 completion releases, with a final proration factor of 18.289133% published by Medtronic on October 14.
When did MiniMed become fully independent?
October 15, 2026 was MiniMed’s first day as a fully independent company, per its release. The stock trades on Nasdaq as MMED and closed its first post completion session at $17.49 on October 16.
What would China’s new biotech export rules prohibit?
The draft catalogue would ban foreign acquisitions of proprietary Chinese platforms in cell and gene therapy, siRNA, and pathogen gain of function research, and require approval for full transfers of target identification technologies in those fields. Out licensing and outsourced services are excluded. Comments close November 15.
Would China’s draft rules stop licensing deals for Chinese drugs?
No. Out licensing agreements are explicitly excluded, and out licensing of target identification technologies would generally be approved, per Fierce Biotech’s report on the draft. Only 5 of 121 cross border out licensing deals in 2026 through July 1 involved ownership transfer, per PharmCube.
How did City Therapeutics stock perform on its first day of trading?
City Therapeutics closed its first session on October 16, 2026 at $22.40, 24.4% above its $18.00 offer price, after pricing an upsized $200.0 million IPO. The close versus offer calculation is ours from the settled exchange close.
Is orforglipron approved in Europe?
Not yet. The CHMP issued a positive opinion for Foundayo (orforglipron) on October 16, 2026 for obesity and type 2 diabetes; a European Commission decision, which usually follows the committee’s recommendation, is the final approval step.
What is the 4Kscore test Labcorp is acquiring?
An FDA approved blood test that helps predict the likelihood of finding aggressive prostate cancer before a biopsy decision. Up to $150 million of the deal’s value is an earnout tied to 4Kscore revenue.
What is Cyclin E1 and why does it matter for azenosertib?
Cyclin E1 is a cell cycle protein whose overexpression marks tumors under replication stress, the vulnerability WEE1 inhibitors like azenosertib exploit. In DENALI Part 1b, Cyclin E1 positive patients showed median overall survival of 15.8 months versus 7.5 in Cyclin E1 negative patients, supporting its use as a selection biomarker, with the caveats that the analysis was interim, retrospective, and a secondary endpoint.
When does ESMO Congress 2026 take place?
October 23 to 27, 2026 in Madrid, Spain. Zentalis presents the DENALI survival data in a rapid oral on October 23, and AbbVie, Lilly, Incyte, Natera, and Eikon all announced presentation slates on Sunday.
What is Lonza’s 2026 guidance?
Reaffirmed at 11% to 12% sales growth in constant currency with a CORE EBITDA margin of 33% to 34%, alongside new midterm targets of low teens average organic growth and a margin in the high 30s.
What results will Disc Medicine discuss on Monday?
Topline results from the Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria, on an 8:00 am ET webcast announced Sunday evening. The announcement did not disclose the results; APOLLO is the trial intended to answer the FDA’s complete response letter.
Did a court rule on the new 340B rebate pilot lawsuit?
Not as of Sunday night, October 18. The suit against the pilot’s second version, filed October 9 in the District of Maine ahead of a January 1, 2027 launch, has no ruling we could find; search results surface the December 2025 restraining order against the first version, which is a different case.
When does Abbott report third quarter earnings?
Wednesday, October 21, 2026, before the market opens, with a call at 8:00 am Central, per the company’s September 30 notice. It is the first major medtech print of the quarter.
Sources
Primary sources: MiniMed completion release, 8-K exhibit 99.1, sec.gov, October 15, 2026; Medtronic completion release, news.medtronic.com, October 15, 2026; Medtronic final exchange offer results release, October 14, 2026; Labcorp and OPKO Health joint release, PR Newswire, October 15, 2026; Zentalis release on DENALI Part 1b overall survival, October 18, 2026; Opus Genetics release on the RYZUMVI presbyopia approval, October 16, 2026; Disc Medicine webcast announcement, October 18, 2026; Veradermics conference call announcement, October 18, 2026; AbbVie UEG Week release, October 17, 2026; Zentalis ESMO presentation release (congress dates), July 17, 2026; Abbott third quarter call notice, September 30, 2026. Settled closing prices from exchange close data; all percentage calculations are our arithmetic.
Trade and wire coverage (attributed): Fierce Biotech on China’s draft export control catalogue, October 16, 2026; Fierce Pharma on the CHMP October opinions, October 16, 2026 (EMA highlights are the primary document); Reuters via affiliate carries on Lonza’s capital markets day, October 14, 2026, and on the Novartis Fabhalta lupus nephritis discontinuation, October 16, 2026; MedTech Dive on the MiniMed separation, the Labcorp deal, and the Edwards Sapien M3 delivery system recall, October 15 to 16, 2026; Fierce Biotech and Endpoints News on Estuary Therapeutics’ $103 million launch, October 16, 2026.
Related coverage
Read our coverage of City Therapeutics’ upsized $200 million IPO pricing and Iambic’s debut session, the MiniMed exchange offer’s final proration and the Anktiva papillary approval, and J&J’s third quarter results and the market’s clearing price verdict.
